首页> 中文期刊> 《山西医药杂志》 >奥美沙坦联合苯磺酸氨氯地平治疗原发性高血压的临床观察

奥美沙坦联合苯磺酸氨氯地平治疗原发性高血压的临床观察

             

摘要

目的:观察分析奥美沙坦联合苯磺酸氨氯地平治疗原发性高血压的临床效果。方法回顾性分析我院在2010年12月至2012年12月收治的118例原发性高血压患者的病历资料,按照是否进行了奥美沙坦的治疗方法将其分为观察组和实验组;观察组患者采用奥美沙坦联合苯磺酸氨氯地平的治疗方法,对照组患者采用单纯苯磺酸氨氯地平的治疗方法;2组分别治疗6周,在此期间观察2组患者出现不良反应等情况,6周之后,对2组患者进行临床疗效的比较。结果观察组治疗后收缩压和舒张压[(140±10)/(86±5)mmHg]与对照组[(142±10)/(88±5)mmHg]相比,差异有统计学意义(P<0.05)。观察组有64%患者有显著效果,对照组有41%的患者有显著效果,2组差异有统计学意义(P<0.05)。观察组患者中有4%的患者出现不良反应,对照组有22%的患者出现不良反应,2组差异有统计学意义(P<0.05)。结论奥美沙坦联合苯磺酸氨氯地平治疗原发性高血压疗效显著且较安全。%Objective To observe and analyze clinical observation on the curative effect of olmesartan combi-ning with amlodipine besylate tablet on the treatment of primary hypertension .Methods Medical records of 118 cases with primary hypertension that were accepted by a hospital from December ,2010 to December ,2012 are ret-rospectively analyzed .They were equally and randomly divided into observation group of which patients adopt the treatment of olmesartan combining with amlodipine besylate tablet and contrast group ,of which patients adopt the treatment of Amlodipine Besylate Tablet .The treatment lasts 6 weeks .During the treatment ,the condition of ad-verse reactions in the two groups would be observed .After six weeks ,the clinical effect of patients in two groups were compared .Results After treatment ,the comparative results of systolic pressure and diastolic pressure in ob-servation group[ (140 ± 10)/(86 ± 5)mmHg]with contrast group[(142 ± 10)/(88 ± 5)mmHg] showed obviously statistically significant difference ( P <0.05) .Sixty-four percent patients in observation group had obvious effect and 41% cases in contrast group had obvious effect .The two groups showed obvious differences .The result of contrast had a statistical significance ( P <0.05) .About 4% patients in observation group reacted with adverse reactions and 22% cases in contrast group reacted with adverse reactions .The result of contrast had a statistical significance ( P <0.05).Conclusion The effect of olmesartan combining with amlodipine besylate tablet on the treatment of primary hypertension is obvious and safe.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号